

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/O6A86A8C440EN.html>

Date: September 2018

Pages: 67

Price: US\$ 3,500.00 (Single User License)

ID: O6A86A8C440EN

Abstracts

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2018

SUMMARY

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. The latest report Orexin Receptor Type 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide.

The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 2, 8 and 2 respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Nicotine Addiction, Insomnia, Binge Eating Disorder, Addiction, Alcohol Addiction, Drug Addiction, Anxiety Disorders, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Narcolepsy, Obstructive Sleep Apnea, Opium (Opioid) Addiction, Panic Disorders, Parkinson's Disease, Pathological Gambling and Sleep Disorders.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies
Involved in Therapeutics Development

Chronos Therapeutics Ltd

Eisai Co Ltd

Heptares Therapeutics Ltd

Idorsia Pharmaceutical Ltd

Indivior Plc

Johnson & Johnson

OptiNose US Inc

Yangtze River Pharmaceutical Group

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles

ACT-539313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-4X3256 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-010018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EORA-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-6641 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3215 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize HCRTR1 for Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones

Featured News & Press Releases

Jul 24, 2018: C4X Discoverys C4X3256 programme awarded \$480k grant from the US National Institute on Drug Abuse

Jul 19, 2018: Eisai announce presentation on lemborexant at (AAIC) 2018

Jul 02, 2018: Eisai to Give Oral Presentation on Results of Phase III Head-to-head Clinical Study of Lemborexant in Insomnia Disorder at 43rd Annual Meeting of the Japan Society of Sleep Research

Jun 11, 2018: Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia

Jun 05, 2018: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting

May 22, 2018: Eisai and Purdue Pharma Announce Key Phase 1 Clinical Studies of Lemborexant to be Presented at the 32nd Annual SLEEP Meeting

Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant

Dec 07, 2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting

Nov 13, 2017: C4XD presents data on its lead addiction programme: Orexin-1 antagonist

Oct 31, 2017: Eisai to Present Latest Data on lemborexant at 10th Clinical Trials on Alzheimer's Disease

Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia

Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor

Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia

Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia

Feb 01, 2016: OptiNose Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional Breath Powered Technology Selected for Norwegian Government Funding

May 20, 2015: Selection of drug candidate from Orexin-1 programme to treat stress-related addictive disorders and entry into pre-clinical development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Chronos Therapeutics Ltd, H2 2018
Pipeline by Eisai Co Ltd, H2 2018
Pipeline by Heptares Therapeutics Ltd, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by Indivior Plc, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by OptiNose US Inc, H2 2018
Pipeline by Yangtze River Pharmaceutical Group, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Chronos Therapeutics Ltd

Eisai Co Ltd

Heptares Therapeutics Ltd

Idorsia Pharmaceutical Ltd

Indivior Plc

Johnson & Johnson

OptiNose US Inc

Yangtze River Pharmaceutical Group

I would like to order

Product name: Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/O6A86A8C440EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O6A86A8C440EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

